Comarum Palustre in Knee Osteoarthritis and Diabetes

• Status: Completed
• Trial end date: 2018-11-25
• Target enrollment: 0
• Participant gender: All

Summary

The study evaluates analgesic, antiinflammatory and metabolic effects of Comarum palustre in patients with knee osteoarthritis (OA) and diabetes mellitus. Patients with osteoarthritis will receive Comarum palustre together with conventional treatment of osteoarthritis and diabetes.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology
• Treatments: Anti-Inflammatory Agents, Non-Steroidal

Criteria

Inclusion Criteria:

• osteoarthritis of the knee fulfilling American College of Rheumatology (ACR) criteria

• diagnosis of type 2 diabetes mellitus

Exclusion Criteria:

• use of NSAIDs one month prior to study entry (paracetamol is allowed)

• pregnancy and lactation

• increased sensitivity to the study drug

• clinically significant renal function impairment

• use of antidepressants

• diagnosis of bipolar disorder

• use of symptomatic slow acting drugs of OA (SYSADOA) one month prior to study entry

• any condition which may lead to difficulties to participation in the study from the viewpoint of Investigator